Keros Therapeutics (KROS)

Keros Therapeutics stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · NASDAQ

$11.40▲ +0.62%

Prices as of Oct 27, 2026 · USD

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

49%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Keros Therapeutics in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Keros Therapeutics

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Keros Therapeutics a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between $10.53 and $12.28; in 9 out of 10, between $9.19 and $14.07. Estimated annual volatility is 40%.

Price, last 12 months (weekly close)

Key numbers

Market cap: $225M
52-week high: $22.55
52-week low: $9.69
Revenue (12 months): $15.0M
Revenue growth (YoY): +6,775.0%
Gross margin: 0.0%
Operating margin: 27.7%
Net margin: 35.7%
Return on equity: -17.2%
Free cash flow (12 months): $-27.2M
Beta: 1.02

What this means

ATLAS does not publish a fair value for KROS right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks KROS has traded between $9.69 and $22.55. Today it is 49.5% below that high and 18% above its low.

On the business: revenue grew 6,775.0% year over year; net margin is 35.7%.

Its beta is 1.02: it moves roughly in line with the market.

About the company

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins.

Want to see everything about Keros Therapeutics?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Keros Therapeutics do?

What is the chance KROS goes up next month?

49%: close to a coin flip. In half of the simulated outcomes, KROS ends the month between $10.53 and $12.28.

How big is Keros Therapeutics and what is its P/E ratio?

Keros Therapeutics's market capitalization is $225M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is KROS?

ATLAS estimates annual volatility at 40%. In a typical month, half of the outcomes end between $10.53 and $12.28.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer